

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 December 2021 (09.12.2021)



(10) International Publication Number
WO 2021/247454 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/46 (2006.01)
C07K 14/54 (2006.01) C12N 15/09 (2006.01)
C07K 16/24 (2006.01) C12N 15/13 (2006.01)

(21) International Application Number:

PCT/US2021/035065

(22) International Filing Date:

31 May 2021 (31.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/032,929 01 June 2020 (01.06.2020) US

(71) Applicant: AVALO THERAPEUTICS, INC. [US/US];
540 Gaither Road, Suite 400, Rockville, Maryland 20850
(US).

(72) Inventors: NEIL, Garry A.; c/o AEVI GENOMIC
MEDICINE, LLC, 1500 Liberty Ridge Drive, Suite 321,
Chesterbrook, Pennsylvania 19087 (US). ZAFIR-LAVIE,
Inbal; c/o AEVI GENOMIC MEDICINE, LLC, 1500 Lib-
erty Ridge Drive, Suite 321, Chesterbrook, Pennsylvania
19087 (US). ROADCAP, Lori; c/o AEVI GENOMIC
MEDICINE, LLC, 1500 Liberty Ridge Drive, Suite 321,
Chesterbrook, Pennsylvania 19087 (US).

(74) Agent: BAUR, Amelia Feulner et al.; MCNEILL BAUR
PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge,
Massachusetts 02140 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

(54) Title: METHODS AND TREATMENT INVOLVING ANTIBODIES TO IL-18




FIG. 1

(57) Abstract: The present disclosure relates to methods of treating and/or detecting respiratory and inflammatory conditions associated with IL-18 by administering an anti-IL-18 antibody, optionally wherein the antibody comprises the six CDRs of SEQ ID NOS: 122, 123, 124, 126, 127, and 128, wherein 122-124 comprise the heavy chain CDRs and 126-128 comprise the light chain CDRs, to subjects having elevated IL-18 levels. Conditions include acute respiratory distress syndrome (ARDS) and hemophagocytic lymphohistiocytosis (HLH)/Macrophage activation syndrome (MAS), optionally wherein the ARDS and HLH/MAS are associated with viral infection, including coronavirus infection.

[Continued on next page]

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*